Latest Headlines

  1. Creatv Bio Opens CLIA-Certified Laboratory To Support Oncology Drug Development 5/13/2026

    Creatv Bio, a Division of Creatv MicroTech, Inc. ("Creatv"), a liquid biopsy-based cancer diagnostic testing company, recently opened its full service CLIA-certified laboratory in Monmouth Junction, NJ.

  2. OpenBind Releases First Open Dataset And AI Model For Drug Discovery 5/13/2026

    Researchers from the University of Oxford, as part of the OpenBind consortium, have published a new dataset and predictive AI model, strengthening the data foundations needed for AI in drug discovery.

  3. Nexentis Technologies Announces Optimization Of Hit Molecule At MitoCareX Bio Representing Key Drug Discovery Milestone 5/13/2026

    Nexentis Technologies Inc. ("Nexentis" or the "Company"), a drug discovery company that also invests in solar energy assets based on the RTB (Ready to Build) business model, today announced that its wholly owned subsidiary, MitoCareX Bio Ltd.

  4. AndzonBio2, The ALBORADA Drug Discovery Institute At The University Of Cambridge And Cambridge Enterprise Announce A Collaboration To Develop First-In-Class Therapeutics For Neuroinflammation 5/13/2026

    AndzonBio2 today announced the signature of agreements with the ALBORADA Drug Discovery Institute (ADDI) at the University of Cambridge and Cambridge Enterprise to advance a new class of therapeutics targeting neuroinflammation, a central driver of multiple neurodegenerative and neurological conditions such as Parkinson's, Alzheimer's, Amyotropic Lateral Sclerosis and other CNS disorders.

  5. Inside Information: Nanoform Signs First Exclusivity Agreement For Ultra-High Concentration Subcutaneous Delivery 5/12/2026

    Helsinki, Finland – Nanoform Finland Plc (“Nanoform”), the medicine performance‑enhancing company, today announced that it has signed an exclusivity agreement with a U.S. biopharmaceutical company (Nasdaq listed, Mcap USD 1Bn+) for the application of Nanoform’s proprietary biologics nanoparticle technology to support the development of differentiated subcutaneous biologic medicines.

  6. Government's Sovereign AI Invests In British-Founded AI Company Redefining How Medicines Are Designed 5/12/2026

    Isomorphic Labs, a London-founded and headquartered company, using AI to design and develop new medicines, has been named as the latest firm to receive investment from the UK Government’s Sovereign AI Fund today (Tuesday 12 May).

  7. Ribo Announces Strategic Collaboration With Insilico Medicine To Accelerate siRNA Drug Development Driven By AI 5/12/2026

    Suzhou Ribo Life Science Co., Ltd. announced that the Company has entered into a strategic collaboration agreement with Insilico Medicine.

  8. Kelun-Biotech Receives Investigational New Drug Approval From CDE For SKB118, A PD-1 x VEGF Bispecific Antibody 5/12/2026

    Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that it has received a clinical trial notice from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) approving the Investigational New Drug (IND) application for PD-1 x VEGF bispecific antibody SKB118 (also known as CR-001) for the treatment of advanced solid tumors.

  9. Partner Therapeutics Announces FDA Approval Of BIZENGRI® (Zenocutuzumab-zbco) For NRG1 Fusion-Positive Cholangiocarcinoma Following Receipt Of FDA Commissioner's National Priority Voucher 5/11/2026

    Partner Therapeutics, Inc. (PTx), a private, fully integrated biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has approved BIZENGRI (zenocutuzumab-zbco) for the treatment of adults with advanced, unresectable or metastatic cholangiocarcinoma harboring a neuregulin 1 (NRG1) gene fusion with disease progression on or after prior systemic therapy.

  10. ACROBiosystems Launches Global License Solution Upgrade For HEK293 Functional Cell Lines, Streamlining Compliance To Accelerate Biopharmaceutical R&D 5/11/2026

    ACROBiosystems announced a major upgrade to its global license solution for HEK293 functional cell lines.